|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, in two distinct CRC mouse models, loss of Mpc1 prior to a tumorigenic stimulus doubled the frequency of adenoma formation and produced higher grade tumors.
|
31813825 |
2020 |
|
Patent ductus arteriosus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TCGA database, paired PDA and adjacent normal pancreatic tissues, PDA tissue array and cell lines were used to determine the levels of MPC-1 and KDM5A expression, and their relationship with the clinicopathologic characteristics and overall survival (OS) of PDA patients.
|
31641207 |
2020 |
|
PATENT DUCTUS ARTERIOSUS 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TCGA database, paired PDA and adjacent normal pancreatic tissues, PDA tissue array and cell lines were used to determine the levels of MPC-1 and KDM5A expression, and their relationship with the clinicopathologic characteristics and overall survival (OS) of PDA patients.
|
31641207 |
2020 |
|
Dermatomyositis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
Diabetes Mellitus
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
Hamartoma Syndrome, Multiple
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this study, we carried out following mRNA expression profile analysis on Cd-treated <i>mpc1-1</i> and wild-type plants.
|
31198086 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, we reveal that MPC1/STAT3 axis plays an important role in the progression of LAC, and our work may promote the development of new therapeutic strategies for LAC.
|
30770798 |
2019 |
|
Lung Diseases, Interstitial
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
Tumor Initiation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Mitochondrial pyruvate carrier 1 (MPC1), a key factor that controls pyruvate transportation in the mitochondria, is known to be frequently dysregulated in tumor initiation and progression.
|
30770798 |
2019 |
|
MYOTONIC DYSTROPHY 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PGC1α promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect.
|
29700317 |
2018 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to clarify the function of MPC1 that affects the malignant potential of ICC.
|
29286150 |
2018 |
|
Biliary Tract Cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated the impact of altering the MPC1 gene expression on the malignant potential of cancer cells using biliary tract cancer cell lines in vitro.
|
29286150 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Low MPC1 expression correlated with poor ICC prognosis and was correlated with tumor invasion and distant metastasis.
|
29286150 |
2018 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MPC1 may therefore serve as an attractive biomarker for the identification of patients with HCC at a high risk of recurrence following curative resection.
|
29805642 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that MPC1 may be a novel prognostic marker and a potential therapeutic target in human GC.
|
29123413 |
2017 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that MPC1 may be a novel prognostic marker and a potential therapeutic target in human GC.
|
29123413 |
2017 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
There are studies showing low levels of MPC1 expression in colon, kidney and lung cancers, and the expression of MPC1 correlates with poor prognosis.
|
27852261 |
2016 |
|
Familial lichen amyloidosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression status of MPC1 and MPC2 in prostate cancer (PCA) is unclear.
|
27852261 |
2016 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition to known markers such as ERBB2 and E-cadherin, novel markers, including BRP44L, MTHFD2 and TIMM17A, were found to be overexpressed in 21T breast cancer cells and verified in additional breast cell lines. mRNA expression analysis as well as immunohistochemistry analysis in breast cancer tissues indicated that expression level of TIMM17A was directly correlated with tumor progression, and survival analysis suggested that TIMM17A was a powerful prognosis factor in breast cancer.
|
20198662 |
2010 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition to known markers such as ERBB2 and E-cadherin, novel markers, including BRP44L, MTHFD2 and TIMM17A, were found to be overexpressed in 21T breast cancer cells and verified in additional breast cell lines. mRNA expression analysis as well as immunohistochemistry analysis in breast cancer tissues indicated that expression level of TIMM17A was directly correlated with tumor progression, and survival analysis suggested that TIMM17A was a powerful prognosis factor in breast cancer.
|
20198662 |
2010 |
|
Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our results identify anti-tumor function of MPC1 in RCC and revealed MPC1 as a novel prognostic biomarker to predict better patient survival.
|
30291323 |
2019 |
|
Multiple Myeloma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
|
31342211 |
2019 |
|
Multiple Myeloma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib.
|
30887866 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our results identify anti-tumor function of MPC1 in RCC and revealed MPC1 as a novel prognostic biomarker to predict better patient survival.
|
30291323 |
2019 |